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Proteomic profiling of cellular steatosis
with concomitant oxidative stress in vitro
Khalida Ann Lockman1, Varanand Htun1, Rohit Sinha1, Philipp Treskes1, Leonard J. Nelson1, Sarah F. Martin2,
Sophie M. Rogers2, Thierry Le Bihan2, Peter C. Hayes1 and John N. Plevris1*
Abstract
Background: Nutrient excess underpins the development of nonalcoholic fatty liver disease (NAFLD). The ensuing
metabolic derangement is characterised by increased cellular respiration, oxidative stress and mitochondrial
impairment. We have previously recapitulated these events in an in vitro cellular steatosis model. Here, we
examined the distinct patterns of protein expression involved using a proteomics approach.
Methods: Human hepatoblastoma C3A cells were treated with a combination of energy substrates; lactate (L),
pyruvate (P), octanoate (O) and ammonia (N). Proteins extracts were trypsinized and analyzed on a capillary HPLC
OrbitrapXL mass spectrometer. Proteins were quantified using a label-free intensity based approach. Functional
enrichment analysis was performed using ToppCluster via Gene Ontology (GO) database.
Results: Of the 1327 proteins identified, 104 were differentially expressed between LPON and untreated cells
(defined as: ≥2 peptides; fold change ≥1.5; p-value <0.05). Seventy of these were upregulated with LPON.
Functional enrichment analysis revealed enhanced protein biosynthesis accompanied by downregulation of
histones H2A type 1-A, H1.2, H1.5 and H1.0I in LPON cells. Lipid binding annotations were also enriched as well as
proteins involved in cholesterol synthesis, uptake and efflux. Increased expression of aldo-keto reductase family 1,
member C1 and C3 suggests enhanced sterol metabolism and increased ROS-mediated lipid peroxidation.
Conclusions: The surge of energy substrates diverts free fatty acid metabolism towards pathways that can mitigate
lipotoxicity. The histones depletion may represent an adaptation to increased protein synthesis. However, this can
also expose DNA to oxidative stress thus should be explored further in the context of NAFLD progression.
Keywords: Nonalcoholic fatty liver, Steatohepatitis, Oxidative stress
Background
Nonalcoholic fatty liver disease (NAFLD) is becoming
increasingly prevalent globally, often presenting along-
side Type 2 diabetes and obesity [1]. According to a re-
cent study, the prevalence of NAFLD in a middle-aged
population living in the United States is 46 % and of
those, 29.9 % were discovered to have progressed to
nonalcoholic steatohepatitis (NASH) [2]. Although
traditionally thought of as a western disease, the preva-
lence of NAFLD is now also high in Asia; as high as
45 % in parts of south Asia and East Asia [3].
NAFLD is characterized by intracellular triglyceride
accumulation within the liver that potentially, in the
presence of inflammation, can progress to NASH and
eventually can lead to liver cirrhosis [4, 5]. Increased free
fatty acids (FFA) delivery to the liver is the crux of
NAFLD development. A dietary surge of FFAs can lead
to triglyceride accumulation and, importantly, it can en-
hance mitochondrial respiration thus increasing the for-
mation of reactive oxygen species (ROS) [6, 7]. A
prominent theory is that the progression from steatosis
to steatohepatitis and cirrhosis in part, is caused by hep-
atic lipotoxicity. The toxicity effects appear to stem from
FFA rather than steatosis per se [8]. Both FFAs and their
metabolites have been implicated in the induction of in-
flammation and apoptosis via an increase in ROS, and
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by activating signalling pathways that can precipitate
apoptosis [9, 10].
The precise molecular mechanisms are yet to be eluci-
dated but are likely to involve complex interactions be-
tween various intra- and extracellular metabolic signalling
networks. Recent advances in proteomics can potentially
unravel these relevant pathways. The systematic protein
profiling achieved by proteomics can identify distinct pat-
terns of protein expression in response to the metabolic
derangement in NAFLD. There have been recent proteo-
mics in vivo studies set to identify suitable markers of
NAFLD progression as well as examining protein expres-
sion in serum samples and liver tissue from patients with
NAFLD [11, 12]. However, these studies are not geared to
differentiate events that occur specifically within the hep-
atocyte from those that have arisen peripherally.
We have previously shown that C3A hepatoblastoma
cells treated with combinations of physiological energy
substrates; lactate (L), pyruvate (P), octanoate (O) and
ammonia (N) in vitro recapitulate the events that have
been proposed to occur in NAFLD [13]. The combin-
ation of these substrates induces significant steatosis.
Importantly, these substrates synergize to enhance tri-
carboxylic acid cycle (TCA) activity hence increased
mitochondrial respiration. The resultant rise in ROS
culminates in morphological and functional alterations
of the hepatic mitochondria. Thus, LPON-induced
cellular steatosis manifests many of the key features
associated with steatohepatitis such as impaired mito-
chondrial function, oxidative stress, and altered glu-
cose metabolism. In this study, using a high-resolution
focused proteomics approach, we examined distinct
patterns of protein expression in our vitro model of
cellular steatosis.
Methods
Cell culture
Human hepatoblastoma C3A cells (CRL-10741, American
Type Culture Collection, Manassas, VA, USA) were cul-
tured in 75 cm2 tissue culture flasks in minimal essential
medium Eagle (MEME) (Sigma, Poole, UK, cat. no.
M0268) with 10 % fetal calf serum (FCS) (Gibco, Life Tech-
nologies, CA, USA, cat. no. 10270) and antibiotics (100 IU/
ml penicillin, 100 mg/ml streptomycin) (Sigma, Poole, UK,
cat. no. P0781) at 37 °C and 5 % CO2 until 70 % confluent.
The medium was changed every 48 h after initial plating.
Cells were passaged every 7–10 days. MEME with FCS in
the experimental plates was supplemented with combina-
tions of octanoate (O) (2 mM) (Sigma, Poole, UK, cat. no.
C2875), lactate (L) (10 mM) (Sigma, Poole, UK, cat. no.
L7022), pyruvate (P) (1 mM) (Sigma, Poole, UK, cat. no.
P5280) and ammonia (N) (4 mM), (Sigma, Poole, UK, cat.
no. A4514). Cells were cultured in the supplemented media
for 72 h prior to experimentation.
Sample preparation
Supernatant from each treatment group was aspirated,
and the cell monolayer was rinsed twice with 2 ml of
phosphate buffered saline (PBS) (Sigma, Poole, UK,
cat. no. D8662) (with added calcium chloride and
magnesium chloride). Further PBS (500 ml) was added
to each well and cells were then gently harvested. The
pellets were kept frozen at −80 °C until proteomics
analysis. For analysis, samples were centrifuged, super-
natant removed and cells were resuspended in 65 μl
urea 8 M (Sigma, Poole, UK, cat. no. U1250). Protein
concentration was quantified using Bradford protein
assay (Bio-Rad, Hertfordshire, UK, cat. no. 500-0205).
Cell pellets (~200 μg protein) were lysed with dithiothreitol
(DTT) 5 mM (Melford Laboratories, Ipswich, UK, cat. no.
MB1015), reduced, alkylated with iodoacetamide 10 mM
(Sigma, Poole, UK, cat. no. I1149), digested with 8 μg tryp-
sin, L-1-Tosylamide-2-phenylethyl chloromethyl ketone
(TPCK) treated, (Worthington Biochem, Lorne Laborator-
ies, Reading, UK, Cat. No. LS003750) overnight at room
temperature. A total of 4 μg peptides were cleaned on Zip-
Tip (Millipore, Hertfordshire, UK, Cat. No. ZTC18S096)
reverse phase tips and 2 μg were loaded on a Capillary-
HPLC-MS. Capillary-HPLC-MS/MS analysis was done
using a system consisting of a micro-pump (1200 binary
HPLC system, Agilent, UK) coupled to a hybrid LTQ-
Orbitrap XL instrument (Thermo-Fisher, UK). Data were
quantified label-free using Progenesis LC-MS in combin-
ation with MASCOT search engine and the Ref_HSapiens
protein database in a similar manner as published previ-
ously (14).
Bioinformatics
Data were quantified label-free as described previously
[14, 15]. Multicharged (2+,3+,4+) ion intensities were
extracted from LC-MS files and MSMS data were
searched using Mascot Version 2.4 (Matrix Science
Ltd, UK) against the Homo Sapiens subset of the NCBI
protein database (34,281 sequences) using a maximum
missed-cut value of 2, variable oxidation (M), N-
terminal protein acetylation and fixed carbamidometh-
ylation (C); precursor mass tolerance was 7 ppm and
MSMS tolerance 0.4 Da. The significance threshold
(p) was < 0.05 (MudPIT scoring). A minimum peptide
cut off score of 20 was set, corresponding to <3 % glo-
bal false discovery rate (FDR) using a decoy database
search. Proteins identified and quantified with two or
more peptide sequences were retained.
Enrichment analysis
Over represented molecular functions and biological pro-
cesses in LPON treated and untreated C3A cells were iden-
tified by ToppCluster via Gene Ontology (GO) database
(https://toppcluster.cchmc.org/) [16]. Enriched functional
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annotations of this proteomics dataset were identified
under GO: molecular function, GO: biological process, and
GO: cellular component. Functional annotations with a p-
Value cutoff of p < 0.05 with Bonferroni correction were
considered. Gene limits were set to default 1 ≤ n ≤ 1500.
Next, proteins were identified using BLAST search to iden-
tify homologous protein sequences from The National
Center for Biotechnology Information (NCBI) database
(www.ncbi.nlm.nih.gov). InterPro terms were also inte-
grated with BLAST-derived GO terms. Enrichment analysis
was then performed again using Blast2GO [17]. Category 4
proteins (Table 1) were used as the background set. Func-
tional annotations with a p-value cutoff of p < 0.05 and
FDR correction <0.05 were considered. All other settings
were kept at default.
Statistical analysis
A two-tailed t-test for independent samples or biological
triplicates was performed on ArcSinh transformed, nor-
mally distributed intensity data. Proteins with p < 0.05
and absolute mean changes of 1.5-fold or larger were
considered significant.
Results
Findings from the proteomics profiling divided into four
categories are summarized in Table 1. Of the 1327 pro-
teins identified, 104 of these met the criteria for Category
1 in Table 1 (defined as: fold change ≥1.5; quantified with
at least two peptides; p-value <0.05) and were considered
significant between LPON and the untreated group.
Of the Category 1 proteins, 70 (67.3 %) were signifi-
cantly upregulated in LPON treated cells (Table 2). Pro-
tein expression in untreated cells were taken to be the
baseline. Hence, a protein was deemed as downregu-
lated in LPON treated cells when its expression met
the criteria for Category 1 (Table 1) and was greater in
untreated cells than that seen in LPON treated cells.
This is demonstrated in Table 3, which shows the
remaining 34 Category 1 proteins (32.7 %) that were
expressed in lower abundance with LPON when com-
pared with the untreated group.
Significantly enriched GO: Molecular Functions of pro-
teins upregulated with LPON (Table 2) and proteins down-
regulated with LPON (Table 3) derived from ToppCluster
are summarized in Tables 4 and 5 respectively.
LPON treated cells
Proteins involved in lipid metabolism were increased
with LPON as evident by GO: molecular function anno-
tations enriched in response to LPON treatment such as
‘carboxylic acid binding’, ‘organic acid binding’ and
‘monocarboxylic acid binding’ (Table 4). Common up-
regulated proteins within these annotations were serum
albumin preprotein (ALB; fold change: 11.33), aldo-keto
reductase family 1 member C1 (AKR1C1; fold change:
2.41), fatty acid binding protein 1 (FABP1; fold change:
2.01), hepatocyte nuclear factor 4-alpha (HNF4A; fold
change: 1.92), and insulin-like growth factor 2 receptor
(IGF2R; fold change: 1.92) (Table 2).
Enrichment analysis by Blast2GO (Fig. 1) found only
“lipid binding”, a broader GO term, to be enriched. Pro-
teins found to be enriched in this set, that were not
found by ToppCluster, included apolipoprotein A-I pre-
proprotein (APOA1; fold change: 4.08), vigilin (HDLBP;
fold change: 2.72), and apolipoprotein E precursor
(APOE; fold change: 2.21).
However, several noteworthy upregulated proteins in-
volved in lipid processing were not found in the
enriched GO: Molecular Function annotations in Table 4
or Fig. 1. These were perilipin-2 (PLIN2; fold change:
10.42), squalene synthase (FDFT1; fold change: 3.22) and
sterol 27-hydroxylase (CYP27A1; fold change: 1.64)
(Table 2). These proteins are included under enriched
GO: biological process annotations ‘lipid localisation’,
‘lipid transport’ and ‘steroids metabolism’.
Three significant GO: Molecular Function annotations
implicating in increase protein synthesis in response to
LPON are ‘translation factor activity, RNA binding’, ‘transla-
tion elongation factor activity’, and ‘unfolded protein bind-
ing’ (Table 4). A protein of interest included in the former
two terms is elongation factor 1-alpha 1 (EEF1A1; fold
change: 1.52) (Table 2). Whilst the latter term implicates
the components of the TCP-1 Ring Complex (TRiC) by in-
cluding T-complex protein 1 subunit alpha isoform a
(TCP1; fold change: 2.01) T-complex protein 1 subunit beta
isoform 1 (CCT2; fold change: 1.68), T-complex protein 1
subunit epsilon (CCT5; fold change: 2.30), T-complex pro-
tein 1 subunit zeta isoform a (CCT6A; fold change: 1.92)
and T-complex protein 1 subunit eta isoform d (CCT7; fold
change: 1.93) (Table 2).
Untreated cells
‘Chromatin binding’ and its more specific child term ‘chro-
matin DNA binding’ were both enriched in untreated cells
(Table 5). In support of this, enrichment analysis by
Table 1 Summary of all identified proteins from proteomics
profiling
Protein
category
Quantified
peptides
P-value
(ANOVA)
Number of
proteins
Ratio between
conditions
1 >2 <0.05 104 >1.5 fold
2 1 <0.05 98 >1.5 fold
3 >1 <0.05 229 <1.5 fold
4 >1 >0.05 896 Not applicable
Proteins identified were divided into 4 categories based on the quantity of
peptides, ratio between conditions and p-value. Differential expression of
proteins between LPON and the untreated cells was considered as significant
if fold-change was ≥1.5, quantified with at least two peptides and p-value
<0.05 (Category 1)
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Table 2 Significantly upregulated proteins in LPON treated cells
Accession Description HGNC
symbol
Peptide
count
Confidence
score
P-
value
Fold change from
control
NP_000468.1 serum albumin preproprotein ALB 4 173.4 0.00 11.33
NP_001113.2 perilipin-2 PLIN2 6 387.7 0.02 10.42
NP_000030.1 apolipoprotein A-I preproprotein APOA1 2 107.5 0.02 4.08
NP_004453.3 squalene synthase FDFT1 3 159.4 0.02 3.22
NP_005327.1 vigilin HDLBP 3 137.1 0.00 2.72
NP_005902.1 S-adenosylmethionine synthase isoform type-2 MAT2A 3 195.1 0.00 2.50
NP_001344.2 aldo-keto reductase family 1 member C1 AKR1C1 4 226.8 0.00 2.41
NP_006627.2 bifunctional methylenetetrahydrofolate dehydrogenase/
cyclohydrolase, mitochondrial precursor
MTHFD2 2 59.6 0.02 2.39
NP_009224.2 complement C4-A preproprotein C4A 3 119.5 0.01 2.36
NP_006382.1 importin-7 IPO7 2 55.6 0.01 2.35
NP_036205.1 T-complex protein 1 subunit epsilon CCT5 4 255.7 0.00 2.30
NP_001407.1 eukaryotic initiation factor 4A-I EIF4A1 7 314.6 0.00 2.28
NP_000032.1 apolipoprotein E precursor APOE 3 152.7 0.00 2.21
NP_001054.1 serotransferrin precursor TF 6 369.9 0.02 2.18
NP_001165908.1 retrotransposon-derived protein PEG10 isoform 3 PEG10 2 185.2 0.01 2.13
NP_149351.1 surfeit locus protein 4 SURF4 2 251.8 0.01 2.13
NP_002769.1 proactivator polypeptide isoform a preproprotein PSAP 4 243.4 0.00 2.09
NP_001952.1 elongation factor 2 EEF2 13 713.0 0.00 2.07
NP_055121.1 hypothetical protein LOC51493 RTCB 2 88.1 0.01 2.05
NP_001434.1 fatty acid-binding protein, liver FABP1 4 329.0 0.02 2.01
NP_110379.2 T-complex protein 1 subunit alpha isoform a TCP1 6 392.6 0.01 2.01
NP_056348.2 bifunctional ATP-dependent dihydroxyacetone
kinase/FAD-AMP lyase (cyclizing)
TKFC 3 169.5 0.03 2.00
NP_000508.1 hemoglobin subunit alpha HBA2 2 80.4 0.01 1.99
NP_001159757.1 T-complex protein 1 subunit eta isoform d CCT7 2 194.3 0.01 1.93
NP_000448.3 hepatocyte nuclear factor 4-alpha isoform b HNF4A 2 109.1 0.00 1.92
NP_001753.1 T-complex protein 1 subunit zeta isoform a CCT6A 5 408.0 0.01 1.92
NP_001650.1 ADP-ribosylation factor 3 ARF3 3 268.5 0.00 1.90
NP_006364.2 synaptic vesicle membrane protein VAT-1 homolog VAT1 3 174.1 0.01 1.89
NP_006262.1 protein S100-A1 S100A1 2 215.4 0.02 1.88
NP_000867.2 cation-independent mannose-6-phosphate receptor precursor IGF2R 3 103.2 0.02 1.88
NP_000383.1 canalicular multispecific organic anion transporter 1 ABCC2 2 104.3 0.05 1.86
NP_001596.2 alanyl-tRNA synthetase, cytoplasmic AARS 3 150.6 0.02 1.81
NP_002286.2 40S ribosomal protein SA RPSA 3 194.7 0.00 1.80
NP_001171669.1 src substrate cortactin isoform c CTTN 2 62.4 0.01 1.80
NP_005882.2 acetyl-CoA acetyltransferase, cytosolic ACAT2 3 159.6 0.02 1.79
NP_001016.1 40S ribosomal protein S23 RPS23 2 63.0 0.00 1.76
NP_056174.2 zinc transporter ZIP14 isoform b SLC39A14 3 178.6 0.02 1.76
NP_003730.4 aldo-keto reductase family 1 member C3 AKR1C3 3 257.7 0.02 1.73
NP_005971.1 protein S100-P S100P 3 164.9 0.02 1.72
NP_002622.2 6-phosphogluconate dehydrogenase, decarboxylating PGD 5 502.0 0.02 1.70
NP_005821.2 28S ribosomal protein S31, mitochondrial precursor MRPS31 2 78.2 0.00 1.68
NP_001012.1 40S ribosomal protein S17 RPS17 5 349.2 0.01 1.68
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Blast2GO (Fig. 2) also found the broader GO term, ‘chro-
matin binding’ to be significantly enriched. Although pro-
teins enriched in the set varied slightly, common proteins
found in these three sets are as follows: histone H1.0
(H1F0; fold change: 1.59), histone H1.5 (HIST1H1B; fold
change: 1.86), histone H1.2 (HIST1H1C; fold change: 3.30),
heterochromatin protein 1-binding protein (HMGN3; fold
change: 1.89). Common proteins found in these two related
terms are as follows: histone H1.0 (H1F0; fold change:
1.59), histone H1.5 (HIST1H1B; fold change: 1.86), histone
H1.2 (HIST1H1C; fold change: 3.30), heterochromatin pro-
tein 1-binding protein (HMGN3; fold change: 1.89).
Although not included in the aforementioned annotations,
other histone H1 proteins were also downregulated in
LPON-treated cells whilst histone H2A type 1-A
(HIST1H2AA; fold change: 4.63) was also found to be the
most downregulated (Table 3).
Discussion
The advancement of proteomics has unquestionably
provided important insight into the pathogenesis of
human NAFLD. We applied this technique to an in vitro
model of cellular steatosis designed to recapitulate the
effects of excessive energy substrates. Our data highlight
several relevant protein changes that occur in the con-
text of intracellular triglyceride accumulation.
Increased fatty acid processing
Proteins involved in lipid metabolism were increased in
the presence of free fatty acids. The rise in albumin (11-
fold) and the abundance of FABP1 suggest enhanced free
fatty acid sequestering/uptake. Indeed, the binding of
free fatty acids to albumin and FABP1 is crucial for pre-
venting lipotoxicity [8]. However, in contrast to our
current study, FABP1 has been found to be down
Table 2 Significantly upregulated proteins in LPON treated cells (Continued)
NP_006422.1 T-complex protein 1 subunit beta isoform 1 CCT2 5 481.5 0.03 1.68
NP_001018146.1 NME1-NME2 protein NME1 2 105.5 0.00 1.67
NP_004035.2 bifunctional purine biosynthesis protein PURH ATIC 5 247.7 0.00 1.67
NP_038203.2 isoleucyl-tRNA synthetase, cytoplasmic IARS 2 95.1 0.02 1.65
NP_000775.1 sterol 26-hydroxylase, mitochondrial precursor CYP27A1 2 130.2 0.03 1.64
NP_006545.1 metaxin-2 MTX2 2 127.2 0.00 1.64
NP_002203.1 eukaryotic translation initiation factor 6 isoform a EIF6 3 267.9 0.00 1.64
NP_006089.1 guanine nucleotide-binding protein subunit beta-2-like 1 GNB2L1 5 233.4 0.00 1.64
NP_001961.1 eukaryotic translation initiation factor 5A-1 isoform B EIF5A 4 164.5 0.04 1.64
NP_631961.1 TATA-binding protein-associated factor 2 N isoform 1 TAF15 2 126.7 0.00 1.63
NP_001002.1 40S ribosomal protein S7 RPS7 3 178.1 0.00 1.62
NP_004387.1 probable ATP-dependent RNA helicase DDX5 DDX5 3 145.9 0.02 1.61
NP_036555.1 60S ribosomal protein L13a RPL13A 2 72.2 0.00 1.61
NP_000996.2 40S ribosomal protein S3 RPS3 6 264.7 0.01 1.60
NP_006752.1 14-3-3 protein epsilon YWHAE 3 221.6 0.00 1.60
NP_055205.2 staphylococcal nuclease domain-containing protein 1 SND1 12 567.8 0.00 1.58
NP_001000.2 40S ribosomal protein S5 RPS5 3 266.6 0.01 1.57
NP_005557.1 L-lactate dehydrogenase A chain isoform 1 LDHA 6 527.9 0.01 1.57
NP_005337.2 heat shock 70 kDa protein 1A/1B HSPA1B 8 517.1 0.01 1.57
NP_061819.2 sialic acid synthase NANS 3 152.4 0.01 1.56
NP_001419.1 alpha-enolase ENO1 14 1032.9 0.02 1.56
NP_733779.1 S-phase kinase-associated protein 1 isoform b SKP1 3 123.7 0.01 1.55
NP_002385.3 4 F2 cell-surface antigen heavy chain isoform c SLC3A2 11 680.1 0.03 1.53
NP_001279.2 chloride intracellular channel protein 1 CLIC1 4 251.6 0.00 1.53
NP_000792.1 peptidyl-prolyl cis-trans isomerase FKBP1A isoform a FKBP1A 2 126.4 0.01 1.52
NP_001393.1 elongation factor 1-alpha 1 EEF1A1 16 996.3 0.00 1.52
NP_003893.2 far upstream element-binding protein 1 FUBP1 2 165.0 0.00 1.52
NP_006392.1 acidic leucine-rich nuclear phosphoprotein
32 family member B
ANP32B 2 149.5 0.02 1.50
Of the 104 proteins that met the criteria for Category 1, 70 were significantly upregulated with LPON
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regulated in patients with NAFLD as well as in animal
models [18]. Although in this study (18) FABP1 was in-
duced by HNF4A expression, it is also important to note
that FABP1 expression in their mice model of NAFLD,
via methionine and choline deficient diet, decreased
gradually over a period of 5 weeks. Likewise, in humans,
Table 3 Significantly upregulated proteins in untreated cells
Accession Description HGNC
symbol
Peptide
count
Confidence
score
P-
value
Fold change from
LPON
NP_734466.1 histone H2A type 1-A HIST1H2AA 5 321.3 0.02 4.63
NP_005310.1 histone H1.2 HIST1H1C 11 734.0 0.02 3.30
NP_057395.1 ATPase inhibitor, mitochondrial isoform 1 precursor ATPIF1 2 53.7 0.05 3.01
NP_002404.1 microsomal glutathione S-transferase 2 MGST2 2 61.3 0.03 2.47
NP_061849.2 sodium-coupled neutral amino acid transporter 2 SLC38A2 2 281.4 0.02 2.34
NP_115520.2 ras-related protein Rab-6C RAB6C 2 78.7 0.04 2.30
NP_000021.1 serine–pyruvate aminotransferase AGXT 2 103.1 0.01 2.03
NP_112487.1 SRA stem-loop-interacting RNA-binding protein,
mitochondrial precursor
SLIRP 2 118.7 0.04 1.99
NP_003283.2 nucleoprotein TPR TPR 3 244.9 0.01 1.91
NP_004233.1 high mobility group nucleosome-binding
domain-containing protein 3 isoform HMGN3a
HMGN3 2 122.5 0.00 1.89
NP_005313.1 histone H1.5 HIST1H1B 6 464.7 0.02 1.86
NP_001070956.1 protein ALEX isoform f GNAS 3 104.8 0.02 1.81
NP_001600.1 short/branched chain specific acyl-CoA
dehydrogenase, mitochondrial precursor
ACADSB 7 517.8 0.01 1.76
NP_056230.1 brain protein 44 MPC2 2 88.0 0.04 1.76
NP_005361.2 ras-related protein Rab-8A RAB8A 2 95.4 0.01 1.71
NP_002148.1 10 kDa heat shock protein, mitochondrial HSPE1 5 356.0 0.00 1.70
NP_006852.1 ras-related protein Rab-35 isoform 1 RAB35 2 92.2 0.03 1.70
NP_003365.1 voltage-dependent anion-selective
channel protein 1
VDAC1 8 807.2 0.01 1.68
NP_001139021.1 thioredoxin domain-containing protein
5 isoform 3
TXNDC5 6 387.9 0.02 1.66
NP_002130.2 heterogeneous nuclear ribonucleoprotein
G isoform 1
RBMX 11 509.6 0.00 1.63
NP_005349.3 LIM domain only protein 7 isoform 1 LMO7 6 317.6 0.04 1.62
NP_079034.3 agmatinase, mitochondrial precursor AGMAT 5 338.0 0.00 1.62
NP_002734.2 glucosidase 2 subunit beta isoform 1 PRKCSH 10 506.0 0.00 1.60
NP_057318.2 long-chain-fatty-acid–CoA ligase 5 isoform a ACSL5 10 561.8 0.01 1.59
NP_005309.1 histone H1.0 H1F0 6 380.0 0.03 1.59
NP_001059.2 DNA topoisomerase 2-beta TOP2B 2 107.4 0.01 1.57
NP_002851.2 delta-1-pyrroline-5-carboxylate synthase isoform 1 ALDH18A1 20 1184.8 0.00 1.57
NP_006293.2 mannosyl-oligosaccharide glucosidase isoform 1 MOGS 4 173.2 0.01 1.57
NP_059980.2 transmembrane emp24 domain-containing
protein 9 precursor
TMED9 3 182.6 0.01 1.57
NP_065737.2 4-aminobutyrate aminotransferase, mitochondrial
precursor
ABAT 11 699.1 0.00 1.57
NP_006017.1 histone H1x H1FX 3 195.5 0.04 1.55
NP_055866.1 endoplasmic reticulum resident protein
44 precursor
ERP44 2 153.0 0.05 1.54
NP_056240.2 DNA-directed RNA polymerase I subunit RPA1 POLR1A 2 42.2 0.01 1.51
NP_057371.2 heterochromatin protein 1-binding protein 3 HP1BP3 4 221.1 0.02 1.51
Thirty-four proteins in Category 1 were significantly upregulated in untreated cells
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NAFLD development is often a slow and insidious
process. Another study discovered that FABP1, in hu-
man samples, was overexpressed in simple steatosis and
under expressed in NASH tissue samples [19].
Similar to that seen in human and rodent NAFLD, tri-
glyceride accumulation in the LPON model is paralleled
by an upregulation of perilipin-2 (PLIN2) [20]. PLIN2 was
the second-most upregulated protein (10-fold) in response
to LPON. Although its precise role in fatty acid metabol-
ism is yet to be determined. PLIN2 expression is thought
to reduce lipolysis hence decreasing the overall triglycer-
ide turnover [21]. It is possible that this represents a pro-
tective mechanism against the deleterious effects of FFA.
In support of this, a study has shown that in the absence
of PLIN2, perilipin-5 was upregulated to enhance fatty
acid oxidation and to protect mitochondria from oxidative
stress induced by fatty acids [22].
The rationale for using octanoate in this study is that
it accelerates β-oxidation resulting in a swift formation
of acetyl-coA akin to that seen with the surge of energy
substrates in human dietary NAFLD. The fate of the su-
perfluous acetyl-coA is crucial in the pathophysiology of
NAFLD. If the flux into TCA cycle is exceeded, acetyl-
coA would be diverted towards non-oxidative pathways
including the mevalonate pathway for cholesterol and
steroid synthesis. In LPON treated cells, the diversion of
Table 4 Summary of enriched GO: Molecular Function terms in LPON treated cells
Enriched GO: molecular
function terms
GO database ID Log of p-value Proteins enriched in set
structural constituent of ribosome GO:0003735 10 MRPS31 RPL13A RPS17 RPS23
RPS3 RPS5 RPS7 RPSA
poly(A) RNA binding GO:0044822 10 CCT6A DDX5 EEF1A1 EEF2 EIF4A1
EIF5A ENO1 FUBP1 GNB2L1 HDLBP
HSPA1B MRPS31 NME1 PEG10 RPL13A
RPS17 RPS23 RPS3 RPS5 RPS7RPSA
RTCB SLC3A2 SND1 TAF15 TCP1 YWHAE
unfolded protein binding GO:0051082 5.5252 CCT2 CCT5 CCT6A CCT7 HSPA1B TCP1
carboxylic acid binding GO:0031406 5.51 AARS AKR1C1 ALB FABP1
HNF4A IGF2R MAT2A YWHAE
organic acid binding GO:0043177 5.4964 AARS AKR1C1 ALB FABP1 HNF4A
IGF2R MAT2A YWHAE
monocarboxylic acid binding GO:0033293 5.1232 AKR1C1 ALB FABP1
HNF4A IGF2R
translation factor activity, RNA binding GO:0008135 4.5729 EEF1A1 EEF2 EIF4A1 EIF5A EIF6
ketosteroid monooxygenase activity GO:0047086 4.3661 AKR1C1 AKR1C3
indanol dehydrogenase activity GO:0047718 4.3661 AKR1C1 AKR1C3
androsterone dehydrogenase activity GO:0047023 4.0662 AKR1C1 AKR1C3
trans-1,2-dihydrobenzene-1,2-diol dehydrogenase activity GO:0047115 4.0662 AKR1C1 AKR1C3
17-alpha,20-alpha-dihydroxypregn-4-en-3-one dehydrogenase activity GO:0047006 4.0662 AKR1C1 AKR1C3
translation elongation factor activity GO:0003746 3.9915 EEF1A1 EEF2 EIF5A
Overrepresented GO: Molecular Function terms were identified by ToppCluster. HGNC symbol is used to display proteins enriched under the GO term. p-value
cutoff for enriched terms was <0.05 with Bonferroni correction applied to minimize false-positive detection
Table 5 Summary of enriched GO: molecular function terms in untreated cells
Enriched GO: molecular function terms GO database ID Log of P-value Proteins enriched in set
chromatin DNA binding GO:0031490 4.9613 H1F0 HIST1H1B HIST1H1C HMGN3
chromatin binding GO:0003682 4.9031 H1F0 HIST1H1B HIST1H1C
HMGN3 RBMX TOP2B TPR
poly(A) RNA binding GO:0044822 3.7078 ALDH18A1 H1F0 H1FX HIST1H1B
HIST1H1C HSPE1 RBMX SLIRP TPR
Overrepresented GO: Molecular Function terms were detected by ToppCluster. P-value cutoff for enriched terms was p-value < 0.05, in the table this is presented
of Log of p-value. Terms included has p-values subjected to Bonferroni correction to minimize false-positive detection. HGNC symbol is used to display proteins
enriched under the GO term
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acetyl-coA towards mevalonate pathway is evident by a
3.2-fold increase in the expression of squalene synthase,
the first committed step to sterol synthesis. Furthermore,
the significant rise in the expression of apolipoprotein
A1 (APOA1), high density lipoprotein binding protein
(HDLBP) and apolipoprotein E (APOE), all of which
were included in the enriched GO: biological process
‘lipid transport’ supports enhanced cholesterol efflux to
meet the demand of increased synthesis. Hepatic choles-
terol synthesis has been shown to be upregulated in hu-
man NAFLD and its concentration correlates with
disease severity [23].
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Fig. 1 Enrichment analysis for LPON treated cells using Blast2GO. a Overrepresented GO: Molecular Function terms in LPON treated cells.
b Enrichment bar chart of significant GO: Molecular Function term demonstrating the percentage of sequences annotated with LPON compared
with the reference set based on the Fishers Exact Test results
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Fig. 2 Enrichment analysis for untreated cells using Blast2GO. a Overrepresented GO: Molecular Function terms in untreated cells. b Enrichment
bar chart of significant GO: Molecular Function term demonstrating the percentage of sequences annotated compared with the reference set
based on the Fishers Exact Test results
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Increase in protein synthesis and evidence for
Endoplasmic Reticulum (ER) stress
LPON treatment enriches proteins involved in protein
biosynthesis. Given the up regulation of many other pro-
teins in our dataset in response to increased metabolic
demand, the concurrent upregulation for translation
elongation factors that facilitates formation of peptide
bonds is expected. Increased expression of TCP-1 Ring
Complex (TRiC) constituents namely chaperon contain-
ing TCP1 (CCT) proteins in response to LPON is also
suggestive of increase protein synthesis. However, it
should be noted that a study on different cell lines, in-
cluding HepG2, found that cancer cell lines tended to
overexpress TRiC proteins and that expression levels did
not necessarily correlate with TRiC activity [24].
Proteins, however, often have more than one function.
eEF1A1, one of the enriched proteins under the annota-
tion ‘Translation Elongation Factor Activity’, may also
have a role in modulating lipotoxicity. eEF1A1 expres-
sion was found to be induced in HepG2 cells in response
to palmitic acid as well as in obese mice with severe
hepatic steatosis and ER stress [25]. ER stress is caused
by an accumulation of unfolded proteins in the ER
lumen; this initiates the unfolded protein response
(UPR) potentially leading to cell death. Although the
precise role of eEF1A1 in mediating lipotoxic cell death
is not known, it is thought eEF1A1 alters the actin cyto-
skeleton leading to cell death in response to ER stress
caused by increased ROS production [26].
Protein synthesis is complex. It involves posttransla-
tional modifications, which are not examined in this
present study. Further, it is an anabolic process that re-
quires ATP. We have previously shown that chronic
LPON treatment diminished mitochondrial respiration
[13]. It is unknown how this would affect ATP formation
in these cells. The finding of decreased expression of
ATPase inhibitor certainly suggests that the cellular de-
mand for ATP is met. The endogenous ATPase inhibitor
is thought to conserve ATP by limiting the consumption
of cellular ATP in the presence of significant mitochon-
drial impairment [27].
Possible mechanism of injury
We have previously shown that LPON treatment re-
sulted in increased ROS formation [13]. It is likely
that increased ROS formation with LPON modulates
protein expression such that cellular defense against
oxidative/electrophilic stress including those from
lipid peroxidation can be mounted. The expression of
AKR1C1 was raised in the LPON model. This is in
concordance with other studies that have shown
AKR1C1 to be upregulated in response to ROS pro-
duction. Further, it is known to reduce byproducts of
lipid peroxidation such as α, β-unsaturated aldehydes
[28]. AKR1C1 upregulation is also associated with in-
creased transcription factor NF-E2-related factor-2
(NRF2) activity, which plays a crucial role in the up-
regulation of antioxidant pathways [29].
Oxidative stress may have also led to the depletion of
histones in the LPON model. The expression levels of
Histone 1 proteins and high mobility group nucleosome-
binding domain-containing protein 3 isoform HMGN3a
(HMGN3), a regulator of chromatin structure, can have
a large effect on the transcription profile of cells. Trad-
itionally, these proteins are seen as transcriptional re-
pressors although in some circumstances they can act as
activators [30, 31]. In our model, a possible explanation
for the diminished histones is that it reflects the overall
reduction in nucleosomes to allow DNA transcription
process [32].
Although chromatin has been found to have an increas-
ingly complex role in DNA damage response and cellular
function, it appears that one of its basic roles remains to
be physical shielding of DNA from damage [33]. It has
been shown that depletion of histones including H1, can
enhance the rate of DNA damage resulting from ionising
radiation [34]. Thus, it is conceivable that histone depleted
regions of DNA with LPON could also be susceptible to
insult by ROS leading to further depletion. Indeed, hepa-
tocytes in NAFLD are associated with DNA damage and
lack of cell cycle progression beyond G1/S phase [35]. In
addition, ROS-induced DNA damage has been shown to
contribute to steatoapoptosis in a high fat diet mouse
model of NAFLD [36].
Therefore, it is possible that chromatin down regula-
tion with LPON represents an adaptation to increased
requirements for DNA transcription in order to cope
with the increased metabolic demand. However, in a
metabolic milieu characterised by increased ROS forma-
tion, this most likely predisposes to ROS-induced DNA
damage. It is also possible that this vicious cycle will in-
crease the risk of mutations and epigenetic modulations
hence the risk for development of hepatocellular carcin-
oma in a background of steatohepatitis [37–39].
Conclusion
In conclusion, the present study has given us a hepatocyte
perspective of the pathogenesis of NAFLD by distilling
key deranged molecular functions from enriched protein
sets. The picture generated from our proteomic analysis
suggests that the surge of energy substrates instigates
processes that limit lipotoxicity and curb further oxidative
stress (Fig. 3). This involves diversion towards non-
oxidative pathways with concomitant rise in the efflux of
lipid from the liver. This is paralleled by mechanisms
geared to cope with increased oxidative stress. The
associated changes in histones and potentially the nucleo-
somes appear to be significant and deserve further study.
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Although these changes most likely represent an adapta-
tion to increased transcription, the role of fatty acid and/
or oxidative stress in mediating these changes and
whether such alterations can increase DNA susceptibility
to further oxidative stress damage should be explored par-
ticularly in the context of hepatocarcinogenesis.
Abbreviations
AKR1C1: aldo-keto reductase family 1 member C1; ALB: albumin;
APOA1: apolipoprotein A1; APOE: apolipoprotein E; DDT: dithiothreitol;
ER: endoplasmic reticulum; FABP: fatty acid binding protein; FCS: foetal calf
serum; FDR: false discovery rate; FFA: free fatty acid(s); HDLBP: high density
lipoprotein binding protein; HNF4A: hepatocyte nuclear factor 4-alpha;
IGF2R: insulin-like growth factor 2 receptor; LPON: lactate pyruvate octanoate
and ammonia; MEME: minimum essential medium Eagle; NAFLD: non-
alcoholic fatty liver disease; NASH: non-alcoholic steatohepatitis; NRF2: NF-E2-
related factor-2; PBS: phosphate buffered saline; PLIN2: perlipin 2;
ROS: reactive oxygen species; TCA: tricarboxylic acid cycle; TPCK: L-1-
Tosylamide-2-phenylethyl chloromethyl ketone; TRiC: TCP-1 Ring Complex;
UPR: unfolded protein response.
Acknowledgement
The authors are grateful to Mrs. Patricia Lee for technical assistance in
cellular culture experiments.
Authors’ contribution
KAL performed cellular experiments and wrote the manuscript. VH and RS
analysed the data and contributed to the manuscript. PT and LN and
contributed to the data collection. SM, SR and TLB performed proteomics
analysis. PCH and JP conceptualized the study and edited the manuscript. All
authors read, edited and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Financial support
Hepatology Laboratory is funded by Biotechnology and Biological Sciences
Research Council (BBSRC). Grant No: BB/L0236687/1, Great Britain.
Author details
1Hepatology Laboratory, University of Edinburgh, 49 Little France Crescent,
Edinburgh EH16 4SB, Scotland, UK. 2Kinetic Parameter Facility, SynthSys -
Centre for Synthetic and Systems Biology, University of Edinburgh,
Edinburgh EH9 3BF, UK.
Received: 25 April 2016 Accepted: 24 June 2016
References
1. Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol
Hepatol. 2013;10:686–90.
2. Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, Contreras M, et al.
Prevalence of nonalcoholic fatty liver disease and nonalcoholic
steatohepatitis among a largely middle-aged population utilizing ultrasound
and liver biopsy: a prospective study. Gastroenterology. 2011;140:124–31.
3. Farrell GC, Wong VW, Chitturi S. NAFLD in Asia–as common and important
as in the West. Nat Rev Gastroenterol Hepatol. 2013;10:307–18.
4. Contos MJ, Sanyal AJ. The clinicopathologic spectrum and management of
nonalcoholic fatty liver disease. Adv Anat Pathol. 2002;9:37–51.
5. Sanyal AJ, Campbell-Sargent C, Mirshahi F, Rizzo WB, Contos MJ, Sterling RK,
et al. Nonalcoholic steatohepatitis: association of insulin resistance and
mitochondrial abnormalities. Gastroenterology. 2001;120:1183–92.
6. Nakamura S, Takamura T, Matsuzawa-Nagata N, Takayama H, Misu H, Noda H,
et al. Palmitate induces insulin resistance in H4IIEC3 hepatocytes through reactive
oxygen species produced by mitochondria. J Biol Chem. 2009;284:14809–18.
Fig. 3 Increased protein synthesis following a surge of energy substrates with concomitant rise in reactive oxygen species. Our proteomic
analysis suggests that increased energy substrates instigates processes that limit lipotoxicity potentially to curb oxidative stress. This involves
diversion towards non-oxidative pathways with concomitant rise in the efflux of lipid from the liver. The associated changes in histones are most
likely to represent an adaptation to increased transcription but whether such alterations can increase DNA susceptibility to further oxidative stress
damage should be explored
Lockman et al. Lipids in Health and Disease  (2016) 15:114 Page 10 of 11
7. Kohli R, Pan X, Malladi P, Wainwright MS, Whitington PF. Mitochondrial reactive
oxygen species signal hepatocyte steatosis by regulating the phosphatidylinositol
3-kinase cell survival pathway. J Biol Chem. 2007;282:21327–36.
8. Neuschwander-Tetri BA. Hepatic lipotoxicity and the pathogenesis of
nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid
metabolites. Hepatology. 2010;52:774–88.
9. Sparagna GC, Hickson-Bick DL, Buja LM, McMillin JB. A metabolic role for
mitochondria in palmitate-induced cardiac myocyte apoptosis. Am J Physiol
Heart Circ Physiol. 2000;279:H2124–32.
10. Egnatchik RA, Leamy AK, Noguchi Y, Shiota M, Young JD. Palmitate-induced
activation of mitochondrial metabolism promotes oxidative stress and
apoptosis in H4IIEC3 rat hepatocytes. Metabolism. 2014;63:283–95.
11. Younossi ZM, Baranova A, Ziegler K, Del Giacco L, Schlauch K, Born TL, et al.
A genomic and proteomic study of the spectrum of nonalcoholic fatty liver
disease. Hepatology. 2005;42:665–74.
12. Bell LN, Theodorakis JL, Vuppalanchi R, Saxena R, Bemis KG, Wang M, et al.
Serum proteomics and biomarker discovery across the spectrum of
nonalcoholic fatty liver disease. Hepatology. 2010;51:111–20.
13. Lockman KA, Baren JP, Pemberton CJ, Baghdadi H, Burgess KE, Plevris-
Papaioannou N, et al. Oxidative stress rather than triglyceride accumulation
is a determinant of mitochondrial dysfunction in in vitro models of hepatic
cellular steatosis. Liver Int. 2012;32:1079–92.
14. Le Bihan T, Grima R, Martin S, Forster T, Le Bihan Y. Quantitative analysis of
low-abundance peptides in HeLa cell cytoplasm by targeted liquid
chromatography/mass spectrometry and stable isotope dilution:
emphasising the distinction between peptide detection and peptide
identification. Rapid Commun Mass Spectrom. 2010;24:1093–104.
15. Yeung EN, Treskes P, Martin SF, Manning JR, Dunbar DR, Rogers SM, et al.
Fibrinogen production is enhanced in an in-vitro model of non-alcoholic
fatty liver disease: an isolated risk factor for cardiovascular events? Lipids
Health Dis. 2015;14:86.
16. Kaimal V, Bardes EE, Tabar SC, Jegga AG, Aronow BJ. ToppCluster: a multiple
gene list feature analyzer for comparative enrichment clustering and network-
based dissection of biological systems. Nucleic Acids Res. 2010;38:W96–102.
17. Conesa A, Gotz S, Garcia-Gomez JM, Terol J, Talon M, Robles M. Blast2GO: a
universal tool for annotation, visualization and analysis in functional
genomics research. Bioinformatics. 2005;21:3674–6.
18. Guzman C, Benet M, Pisonero-Vaquero S, Moya M, Garcia-Mediavilla MV,
Martinez-Chantar ML, et al. The human liver fatty acid binding protein
(FABP1) gene is activated by FOXA1 and PPARalpha; and repressed by C/
EBPalpha: Implications in FABP1 down-regulation in nonalcoholic fatty liver
disease. Biochim Biophys Acta. 2013;1831:803–18.
19. Charlton M, Viker K, Krishnan A, Sanderson S, Veldt B, Kaalsbeek AJ, et al.
Differential expression of lumican and fatty acid binding protein-1: new
insights into the histologic spectrum of nonalcoholic fatty liver disease.
Hepatology. 2009;49:1375–84.
20. Motomura W, Inoue M, Ohtake T, Takahashi N, Nagamine M, Tanno S, et al.
Up-regulation of ADRP in fatty liver in human and liver steatosis in mice fed
with high fat diet. Biochem Biophys Res Commun. 2006;340:1111–8.
21. Listenberger LL, Ostermeyer-Fay AG, Goldberg EB, Brown WJ, Brown DA.
Adipocyte differentiation-related protein reduces the lipid droplet
association of adipose triglyceride lipase and slows triacylglycerol turnover.
J Lipid Res. 2007;48:2751–61.
22. McManaman JL, Bales ES, Orlicky DJ, Jackman M, MacLean PS, Cain S, et al.
Perilipin-2-null mice are protected against diet-induced obesity, adipose
inflammation, and fatty liver disease. J Lipid Res. 2013;54:1346–59.
23. Min HK, Kapoor A, Fuchs M, Mirshahi F, Zhou H, Maher J, et al. Increased
hepatic synthesis and dysregulation of cholesterol metabolism is associated
with the severity of nonalcoholic fatty liver disease. Cell Metab. 2012;15:665–74.
24. Boudiaf-Benmammar C, Cresteil T, Melki R. The cytosolic chaperonin CCT/
TRiC and cancer cell proliferation. PLoS One. 2013;8:e60895.
25. Stoianov AM, Robson DL, Hetherington AM, Sawyez CG, Borradaile NM.
Elongation factor 1A-1 Is a mediator of hepatocyte lipotoxicity partly
through its canonical function in protein synthesis. PLoS One. 2015;10:
e0131269.
26. Borradaile NM, Buhman KK, Listenberger LL, Magee CJ, Morimoto ET, Ory
DS, et al. A critical role for eukaryotic elongation factor 1A-1 in lipotoxic cell
death. Mol Biol Cell. 2006;17:770–8.
27. Campanella M, Parker N, Tan CH, Hall AM, Duchen MR. IF(1): setting the
pace of the F(1)F(o)-ATP synthase. Trends Biochem Sci. 2009;34:343–50.
28. Burczynski ME, Sridhar GR, Palackal NT, Penning TM. The reactive oxygen
species–and Michael acceptor-inducible human aldo-keto reductase
AKR1C1 reduces the alpha, beta-unsaturated aldehyde 4-hydroxy-2-nonenal
to 1,4-dihydroxy-2-nonene. J Biol Chem. 2001;276:2890–7.
29. Jung KA, Choi BH, Nam CW, Song M, Kim ST, Lee JY, et al. Identification of
aldo-keto reductases as NRF2-target marker genes in human cells. Toxicol
Lett. 2013;218:39–49.
30. Bustin M, Catez F, Lim JH. The dynamics of histone H1 function in
chromatin. Mol Cell. 2005;17:617–20.
31. Rochman M, Taher L, Kurahashi T, Cherukuri S, Uversky VN, Landsman D,
et al. Effects of HMGN variants on the cellular transcription profile. Nucleic
Acids Res. 2011;39:4076–87.
32. Celona B, Weiner A, Di Felice F, Mancuso FM, Cesarini E, Rossi RL, et al.
Substantial histone reduction modulates genomewide nucleosomal
occupancy and global transcriptional output. PLoS Biol. 2011;9:e1001086.
33. Sulli G, Di Micco R, d’Adda di Fagagna F. Crosstalk between chromatin state
and DNA damage response in cellular senescence and cancer. Nat Rev
Cancer. 2012;12:709–20.
34. Elia MC, Bradley MO. Influence of chromatin structure on the induction of DNA
double strand breaks by ionizing radiation. Cancer Res. 1992;52:1580–6.
35. Aravinthan A, Scarpini C, Tachtatzis P, Verma S, Penrhyn-Lowe S, Harvey R,
et al. Hepatocyte senescence predicts progression in non-alcohol-related
fatty liver disease. J Hepatol. 2013;58:549–56.
36. Daugherity EK, Balmus G, Al Saei A, Moore ES, Abi Abdallah D, Rogers AB,
et al. The DNA damage checkpoint protein ATM promotes hepatocellular
apoptosis and fibrosis in a mouse model of non-alcoholic fatty liver disease.
Cell Cycle. 2012;11:1918–28.
37. Cooke MS, Evans MD, Dizdaroglu M, Lunec J. Oxidative DNA damage:
mechanisms, mutation, and disease. FASEB J. 2003;17:1195–214.
38. Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and
hepatocellular carcinoma: a weighty connection. Hepatology. 2010;51:1820–32.
39. Lim SO, Gu JM, Kim MS, Kim HS, Park YN, Park CK, et al. Epigenetic changes
induced by reactive oxygen species in hepatocellular carcinoma: methylation of
the E-cadherin promoter. Gastroenterology. 2008;135:2128–40. 2140 e2121-2128.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Lockman et al. Lipids in Health and Disease  (2016) 15:114 Page 11 of 11
